Take2 Health was Recognised as the Rising Star Company by Deloitte Hong Kong
Take2 Health was honoured to be named the Rising Star Company in the 2021 Deloitte Hong Kong Technology Fast 20 program on Dec 15, 2021.
The 2021 Hong Kong Rising Star award acknowledges the outstanding performances of impactful start-ups with leading technologies and enormous growth potential in its industry. Thank you, Deloitte, for recognising our relentless pursuit of promoting early nasopharyngeal cancer (NPC) detection through the use of ground-breaking technologies combining PCR and NGS (Next-generation Sequencing), and with the mission to guard the health of everyone. In the past year, we had successfully collaborated with numerous clinics & hospitals in Hong Kong to provide comprehensive coverage of our test within the territory.
At present, we are committed to building a digitalised platform to enable the community's easy access to our comprehensive medical solutions. So once again, a huge thank you to Deloitte, and we will keep up the good work.
More Latest News
Nasopharyngeal Cancer Screening Results May “Predict” Development of Related Cancer and Improve Early Diagnosis, CUHK Study Finds
A recent study conducted by The Chinese University of Hong Kong (CUHK)’s Faculty of Medicine (CU Medicine) has shown that individuals with detectable plasma Epstein–Barr virus (EBV) DNA but without an immediately identifiable nasopharyngeal cancer (NPC) after further investigation with nasal endoscopic examination and magnetic resonance imaging (MRI), have a higher risk of developing NPC in 3 to 5 years, up to 17 times higher than those tested “negative” in the test. The non-invasive liquid biopsy techniques not only could be used for early cancer detection but may also indicate the risk for future cancer development.
Promoting NPC Awareness across the City
Joining Hands with Bowtie to Sponsor the Take2 Prophecy™ Test for Nasopharyngeal Cancer to the High-risk Group
Awarded as The Company with the Most Investment Potential & The Top Breakthrough Innovation
Take2 Health are privileged to have participated in the first ZAODX World Conference on Early Detection of Cancer, and are very honoured to be awarded as The Company with the Most Investment Potential (金篩獎‧最具投資價值潛力企業) as well as The Top Breakthrough Innovation (金篩獎‧突破性創新獎)
